摘要
至第一个线粒体DNA点突变在1988年证实与Leber遗传性视神经病变(LHON)有关以来,已经过去了二十多年。随后,我们对遗传性视神经病变分子基础以及他们的临床特征和发病机制有了相当的了解。很明显,绝大多数的遗传视神经病变有原发性的或间接的影响线粒体功能,证明了“线粒体视神经病变”的定义。尽管这些进展中有许多未解决的特征仍然需要被解释,例如在LHON和显性视神经萎缩(DOA)的不完全外显率和可变的临床表现力,在LHON中的性别患病率和在LHON和DOA中复杂的基因/环境的相互作用。这篇综述的主题是线粒体视神经病变的分子基础的最新研究进展。尤其是我们分析了线粒体生物合成在强调不完全外显率和可变的临床表现补偿机制中的作用,及其在未来治疗方法的可行设计。
关键词: 显性视神经萎缩,环境诱因,基因修饰,Leber遗传性视神经病变,Leber遗传性视神经病变,线粒体DNA,OPA1,视神经病变。
Current Molecular Medicine
Title:Genetic Basis of Mitochondrial Optic Neuropathies
Volume: 14 Issue: 8
Author(s): A. Maresca, L. Caporali, D. Strobbe, C. Zanna, D. Malavolta, C. La Morgia, M.L. Valentino and V. Carelli
Affiliation:
关键词: 显性视神经萎缩,环境诱因,基因修饰,Leber遗传性视神经病变,Leber遗传性视神经病变,线粒体DNA,OPA1,视神经病变。
摘要: Over two decades have elapsed since the first mtDNA point mutation was associated with Leber’s hereditary optic neuropathy (LHON) in 1988. We have subsequently witnessed a substantial understanding of the molecular basis of hereditary optic neuropathies, as well as of their clinical features and pathogenic mechanisms. It became clear that the large majority of genetic optic neuropathies have a primary or an indirect involvement of mitochondrial functions, justifying the definition of “mitochondrial optic neuropathies”. Despite this progress many unsolved features remain to be understood, such as incomplete penetrance and variable clinical expressivity in LHON and dominant optic atrophy (DOA), gender prevalence in LHON, and complex gene/environment interactions in both LHON and DOA. The most recent advancement in our understanding of the molecular basis of mitochondrial optic neuropathies is the topic of this review. In particular, we analyze the role that mitochondrial biogenesis may play in the compensatory mechanisms that underlie incomplete penetrance and clinical expressivity, a scenario relevant for the possible design of future therapeutic approaches.
Export Options
About this article
Cite this article as:
Maresca A., Caporali L., Strobbe D., Zanna C., Malavolta D., Morgia La C., Valentino M.L. and Carelli V., Genetic Basis of Mitochondrial Optic Neuropathies, Current Molecular Medicine 2014; 14 (8) . https://dx.doi.org/10.2174/1566524014666141010132627
DOI https://dx.doi.org/10.2174/1566524014666141010132627 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery
Current Neuropharmacology Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Minocycline Repurposing in Critical Illness: Focus on Stroke
Current Topics in Medicinal Chemistry Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design Trends in Mitochondrial Therapeutics for Neurological Disease
Current Medicinal Chemistry Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research Fabry Disease Cardiomyopathy: from Genes to Clinical Manifestations
Current Pharmaceutical Biotechnology A Review of Neuroprotective Agents
Current Medicinal Chemistry Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Targeting Platelet-Neutrophil Interactions in Giant-Cell Arteritis
Current Pharmaceutical Design Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease
CNS & Neurological Disorders - Drug Targets Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration
Current Neuropharmacology Melanocortins As Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives
Current Medicinal Chemistry Mitochondrial-Targeted Plastoquinone Derivatives. Effect on Senescence and Acute Age-Related Pathologies
Current Drug Targets Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology